retatrutide phase 2 trial type 2 diabetes weight loss 2024 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Retatrutide—A Game Changer in Obesity

Some people reach their optimal retatrutide dose in 13 weeks

In a 2018 analysis of clinical trial data, several researchers working with Novo Nordisk, the drugmaker for Ozempic and Wegovy, found that the drugs were safe and effective in adults over age 65, but noted that older adults reported discontinuation due to gastrointestinal issues at a higher rate than younger participants did

Cheng et al

Semaglutide May Be Considered When A patient is an appropriate candidate for GLP-1 therapy and needs medical support for appetite, weight, blood sugar, and cardiometabolic risk

More muscle translates into a higher resting metabolism, which is crucial for long-term weight management

Weight loss isnt just about aesthetics